Regimen Reference Order – GENU – enfortumab vedotin

ARIA: GENU - [enfortumab vedotin]

Planned Course: **Every 28 days (Days 1, 8 and 15) until disease progression or unacceptable toxicity**

Indication for Use: **Urothelial Carcinoma; Locally Advanced or Metastatic**

CVAD: At Provider's Discretion

Proceed with treatment if:

- ***ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L***
- ***Blood glucose less than 13.9 mmol/L***
  - **Contact Physician if parameters are not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GENU – enfortumab vedotin

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Days 1, 8, 15		
ondansetron	8 mg	Orally 30 minutes pre-chemotherapy
enfortumab vedotin	1.25 mg/kg; maximum dose 125 mg	IV in normal saline 50 mL over 30 minutes

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

Baseline

- Hemoglobin A1C as per Physician Orders

Days 1, 8, 15

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin and glucose as per Physician Orders
- Hemoglobin A1C as clinically indicated as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Patient should be instructed to notify clinic if they develop a skin rash
- Patient should be instructed to notify clinic of blurred vision or dry eyes
- Patient should be instructed to monitor for signs of hyperglycemia (excessive thirst, urinating more often than usual or higher amount of urine than usual, increased appetite with weight loss)
- enfortumab vedotin has potential for significant drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- enfortumab vedotin can cause peripheral neuropathy
- enfortumab vedotin can cause severe hyperglycemia and diabetic ketoacidosis
- enfortumab vedotin can cause severe cutaneous reactions
- enfortumab vedotin can cause ocular disorders